These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35192139)

  • 21. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
    Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
    Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
    Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
    Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Tumor Microenvironment in Ovarian Cancer Ascites.
    Almeida-Nunes DL; Mendes-Frias A; Silvestre R; Dinis-Oliveira RJ; Ricardo S
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ablation of hematopoietic stem cell derived adipocytes reduces tumor burden in syngeneic mouse models of high-grade serous carcinoma.
    Woodruff ER; Bailey CA; To F; Manda V; Maltzahn JK; Sullivan TM; Boorgula MP; Recouvreux MS; Vianzon R; Conrad B; Gavin KM; Jordan KR; Klemm DJ; Orsulic S; Bitler BG; Watson ZL
    bioRxiv; 2024 Sep; ():. PubMed ID: 39345441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell Origins of High-Grade Serous Ovarian Cancer.
    Kim J; Park EY; Kim O; Schilder JM; Coffey DM; Cho CH; Bast RC
    Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30424539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
    Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harnessing natural killer cells for the treatment of ovarian cancer.
    Hoogstad-van Evert JS; Bekkers R; Ottevanger N; Jansen JH; Massuger L; Dolstra H
    Gynecol Oncol; 2020 Jun; 157(3):810-816. PubMed ID: 32268953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
    Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
    Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.
    Ghoneum A; Almousa S; Warren B; Abdulfattah AY; Shu J; Abouelfadl H; Gonzalez D; Livingston C; Said N
    Semin Cancer Biol; 2021 Dec; 77():83-98. PubMed ID: 33476723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.
    Gutkin DW; Shurin MR; El Azher MA; Shurin GV; Velikokhatnaya L; Prosser D; Shin N; Modugno F; Stemmer P; Elishaev E; Lokshin A
    Cancer Biomark; 2019; 26(4):471-479. PubMed ID: 31658047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural killer cell-based strategies for immunotherapy of cancer.
    Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
    Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Emerging Role of the Single-Cell and Spatial Tumor Microenvironment in High-Grade Serous Ovarian Cancer.
    Launonen IM; Vähärautio A; Färkkilä A
    Cold Spring Harb Perspect Med; 2023 Oct; 13(10):. PubMed ID: 37553211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer.
    Lee MY; Allen CT
    Head Neck; 2020 Sep; 42(9):2722-2733. PubMed ID: 32275098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.